Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 6/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886839 | 0.94 | MAPK14 (0.51) | MAPK14EPHX2NR1H4PPARAPTGER4 | |
| SCHEMBL5886848 | 0.92 | CCR1 (0.43) | MAPK14EPHX2NR1H4RORCMAPK8 | |
| SCHEMBL5887080 | 0.92 | EPHX2 (0.42) | MAPK14EPHX2NR1H4RORCMAPK8 | |
| SCHEMBL5887029 | 0.91 | MAPK14 (0.48) | MAPK14EPHX2NR1H4PPARAPTGER4 | |
| SCHEMBL5886732 | 0.91 | MAPK14 (0.48) | MAPK14EPHX2NR1H4PPARAPTGER4 | |
| SCHEMBL5887053 | 0.90 | MAPK14 (0.47) | MAPK14EPHX2NR1H4RORCMAPK8 | |
| SCHEMBL5886785 | 0.89 | EPHX2 (0.40) | MAPK14EPHX2NR1H4RORCMAPK8 | |
| SCHEMBL5886905 | 0.89 | RORC (0.41) | MAPK14EPHX2NR1H4RORCMAPK8 | |
| SCHEMBL5886807 | 0.89 | MAPK14 (0.46) | MAPK14EPHX2NR1H4PPARAPTGER4 | |
| SCHEMBL5886928 | 0.89 | MAPK14 (0.46) | MAPK14EPHX2NR1H4MAPK8PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAPK14 1051/4885EPHX2 2968/4885NR1H4 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.